메뉴 건너뛰기
The Lancet
Volumn 372, Issue 9652, 2008, Pages 1785-1786
Gefitinib or docetaxel in advanced non-small-cell lung cancer
Author keywords

[No Author keywords available]
Indexed keywords

BIOLOGICAL MARKER; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; NAVELBINE;
EID: 56249092818     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61741-9     Document Type: Note
Times cited : (6)
References (9)
  • 1
    • 56249109644 scopus 로고    scopus 로고
    • Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
    • Kim E.S., Hirsh V., Mok T., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372 (2008) 1809-1818
    • (2008) Lancet , vol.372 , pp. 1809-1818
    • Kim, E.S.1    Hirsh, V.2    Mok, T.3
  • 2
    • 22044445517 scopus 로고    scopus 로고
    • Erlotinib in previously treated non-small-cell lung cancer
    • Shepherd F.A., Rodrigues P.J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
    • (2005) N Engl J Med , vol.353 , pp. 123-132
    • Shepherd, F.A.1    Rodrigues, P.J.2    Ciuleanu, T.3
  • 3
    • 27544503230 scopus 로고    scopus 로고
    • Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
    • Thatcher N., Chang A., Parikh P., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 (2005) 1527-1537
    • (2005) Lancet , vol.366 , pp. 1527-1537
    • Thatcher, N.1    Chang, A.2    Parikh, P.3
  • 4
    • 33750962024 scopus 로고    scopus 로고
    • Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer
    • Hirsch F.R., Varella-Garcia M., Bunn Jr. P.A., et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 24 (2006) 5034-5042
    • (2006) J Clin Oncol , vol.24 , pp. 5034-5042
    • Hirsch, F.R.1    Varella-Garcia, M.2    Bunn Jr., P.A.3
  • 5
    • 52049090365 scopus 로고    scopus 로고
    • Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21
    • Zhu C.-Q., da Cunha Santos G., Ding K., et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 26 (2008) 4268-4275
    • (2008) J Clin Oncol , vol.26 , pp. 4268-4275
    • Zhu, C.-Q.1    da Cunha Santos, G.2    Ding, K.3
  • 6
    • 47949114668 scopus 로고    scopus 로고
    • Detection of mutations in EGFR in circulating lung-cancer cells
    • Maheswaran S., Sequist L.V., Nagrath S., et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359 (2008) 366-377
    • (2008) N Engl J Med , vol.359 , pp. 366-377
    • Maheswaran, S.1    Sequist, L.V.2    Nagrath, S.3
  • 7
    • 52049096854 scopus 로고    scopus 로고
    • Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study
    • Crino L., Zatloukal P., Reck M., et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 26 (2008) 4253-4260
    • (2008) J Clin Oncol , vol.26 , pp. 4253-4260
    • Crino, L.1    Zatloukal, P.2    Reck, M.3
  • 8
    • 45149120506 scopus 로고    scopus 로고
    • Molecular selection of patients for first-line treatment of advanced non-small cell lung cancer with epidermal growth factor inhibitors: not quite ready for prime time
    • Shepherd F.A. Molecular selection of patients for first-line treatment of advanced non-small cell lung cancer with epidermal growth factor inhibitors: not quite ready for prime time. J Clin Oncol 26 (2008) 2426-2427
    • (2008) J Clin Oncol , vol.26 , pp. 2426-2427
    • Shepherd, F.A.1
  • 9
    • 0034069620 scopus 로고    scopus 로고
    • Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
    • Shepherd F.A., Dancey J., Ramlau R., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18 (2000) 2095-2103
    • (2000) J Clin Oncol , vol.18 , pp. 2095-2103
    • Shepherd, F.A.1    Dancey, J.2    Ramlau, R.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.